Is Selank FDA approved?

No. Selank is a registered medicine in Russia, used as an anxiolytic, but it has never been FDA-approved. In the US it is sold as an unregulated research chemical or compounded, so its US status is unapproved.

How is Selank dosed in Russian clinical use?

It is given intranasally, commonly cited around 400–900 mcg per dose, two to three times daily, often as a percentage nasal solution. These figures describe Russian clinical and community practice rather than an FDA-labeled regimen.

Has the FDA said anything specific about Selank?

Yes — the FDA has raised immunogenicity concerns about compounded Selank, meaning the risk that impurities in a compounded preparation could provoke an immune response. That is on top of the general unknowns of an unregulated product.

Dosage Guide · Approved abroad · not FDA-approved

Selank Dosage: Russian Clinical Use vs US Status

Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced

← Selank encyclopedia entry · See also: Semax dosage · Regulatory tracker

🌐 Status: approved in Russia, not by the FDA

Selank is a registered medicine in Russia (an anxiolytic developed at the Institute of Molecular Genetics) but has never been FDA-approved. In the US it circulates as an unregulated research chemical or a compounded preparation — and the FDA has specifically flagged immunogenicity concerns for compounded Selank. The dosing below reflects Russian clinical and community practice, documented for education, not offered as instructions for US self-use.

The short version

Selank is a synthetic analog of the immune-modulating peptide tuftsin, used intranasally and studied in Russia primarily as an anxiolytic — an anti-anxiety agent — that, unlike benzodiazepines, is reported not to cause sedation, dependence, or withdrawal. Like its sibling Semax, it is the rare peptide here with a real regulated history, just not in the US, so its dosing reads "approved there, unapproved here."

Intranasal dosing as reported

Russian clinical and community sources most commonly describe the following intranasal range. These are descriptive; US product is not the regulated Russian medicine.

Parameter	Commonly reported
Amount	~400–900 mcg per dose
Frequency	2–3× daily
Route	Intranasal (drops/spray)
Form	Often a percentage solution

A pattern often described in the nootropic community pairs Selank in the morning with Semax later in the day, on the rationale that one is calming and the other is activating. That is a community practice, not a validated combination protocol.

The US picture and the immunogenicity caveat

The single most Selank-specific point is the FDA's immunogenicity concern about compounded versions — the worry that impurities could trigger an immune reaction. Combined with the general problems of unregulated injectables and nasal solutions (unverified purity, dose, and sterility), this is the dominant safety consideration for US-sourced Selank. Selank's clinical record in Russia is described as clean, but that record was built on the regulated product, not on research-chemical vials. See the Regulatory Status Tracker.

Frequently asked questions

Is Selank addictive like a benzodiazepine?

Its reported advantage is that, in Russian clinical use, it does not produce the sedation, tolerance, or withdrawal associated with benzodiazepines — but that profile comes from the regulated product and supervised use.

Is it the same as Semax?

No; they are different peptides from the same Russian program, with Selank framed as anxiolytic and Semax as pro-cognitive. See the Semax dosage page.

Is it banned in sport?

As with Semax, lacking approval by major Western regulators means anti-doping frameworks may treat it as a substance without approved therapeutic use; assume it is potentially prohibited and verify.

Sources

Russian Federation drug registration (Selank); Institute of Molecular Genetics, Russian Academy of Sciences.
Zozulia AA, et al. Selank in generalized anxiety disorder (Russian clinical study).
U.S. FDA — Drugs@FDA database (no Selank approval); FDA statements on compounded-peptide immunogenicity.

Medical disclaimer: Education only, not medical advice. Selank is not FDA approved; US-sourced product is unregulated. Dosing figures reflect Russian clinical/community practice, not a recommendation. Consult a licensed clinician.